Aktuellt
SENASTE
Redeye is encouraged to learn about the progress with Vicore’s VP03 program and the acceleration of the first compound, C106, into clinic (application due in Q2). The company has further developed its internal drug development capacity, with four additional A2TR agonistic compounds expected to be ready by the end of 2022. This indicates the beginning of a transition into a platform company with a broader clinical pipeline. Vicore will host an R&D day in March and update the market further - we look forward to get further information about the program.
LÄS MER
